NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.

NCT Number	NCT05837455
Lead Sponsor	Washington University School of Medicine Collaborators: Swim Across America, The Foundation for Barnes-Jewish Hospital
Conditions	Breast Cancer, Cancer of the Breast
Enrollment	81 participants
Start Date	2024-05-30
Primary Completion	2027-11-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-13